GEORGE LAM: Open Payments
NPI 1467961565 · SOUTH PASADENA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,477 in 72 payments from 9 companies in 2025. Trend: 2023 $1,426 · 2024 $2,508 · 2025 $2,477
Food & beverage: $2,457Education: $20
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 7 | $496 |
| Otsuka America Pharmaceutical, Inc. | 13 | $380 |
| Vanda Pharmaceuticals Inc. | 9 | $378 |
| Alkermes, Inc. | 11 | $368 |
| Teva Pharmaceuticals USA, Inc. | 12 | $282 |
| E.R. Squibb & Sons, L.L.C. | 11 | $279 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $163 |
| Neurocrine BioSciences, Inc. | 4 | $109 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
Products named: INVEGA SUSTENNA, FANAPT, COBENFY, REXULTI, ARISTADA, UZEDY, CAPLYTA, LYBALVI.
Industry payments across CA — which companies pay providers there.
